Article Details

Chemoimmunotherapy may be preferable for KRAS wild-type NSCLC

Retrieved on: 2021-04-19 13:07:30

Tags for this article:

Click the tags to see associated articles and topics

Chemoimmunotherapy may be preferable for KRAS wild-type NSCLC. View article details on hiswai:

Excerpt

The study included data from the Flatiron Health database on 1127 patients with nonsquamous histology, PD-L1 expression levels of at least 50%, ...

Article found on: www.medwirenews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up